Transdisciplinary Center for Research in Psychoactive Substances
A mass of neuronal dendrites glows with activity

Publications

Selected Publications by TCRPS Investigators and Researchers

  • Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29, 2473–2480 (2023). https://doi.org/10.1038/s41591-023-02565-4
  • Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843–853. doi:10.1001/jama.2023.14530
  • Miller, M., Rosa, W., Rinaldi, A., Addicott, K., Spence, D., Beaussant, Y. Applying key lessons from the palliative care movement to inform psychedelic-assisted therapy. Psychedelic Medicine. Epub 2023 May 15. doi: 10.1089/psymed.2022.0009
  • Brett J, Knock E, Korthuis PT, Liknaitzky P, Murnane KS, Nicholas CR, Patterson JC II and Stauffer CS (2023) Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Front. Psychiatry 14:1123424.  doi: 10.3389/fpsyt.2023.1123424
  • Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022 Apr 1;233:109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID: 35286849.
  • Rosa, W., Sager, Z., Miller, M. R., Bjerre, C., Bernstein, I… Beaussant, Y. (2022). Top ten tips palliative care clinicians should know about psychedelic-assisted therapy. Journal of Palliative Medicine, 25(8), 1273-1281. doi:  10.1089/jpm.2022.0036
  • Lehto, R. H., Miller, M., Sender, J. (2022). Emerging trends in managing cancer-related distress: The role of psilocybin-assisted psychotherapy. Journal of Holistic Nursing, 40(3), 265-280. doi: 10.1177/08980101211039086
  • Raison CL, Jain R, Penn AD, Cole SP, Jain S. Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. Front Psychiatry. 2022 Mar 15;13:831092. doi: 10.3389/fpsyt.2022.831092. PMID: 35370864; PMCID: PMC8965278.
  • Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot’alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. doi: 10.1038/s41591-021-01336-3. Epub 2021 May 10. PMID: 33972795; PMCID: PMC8205851.
  • Matthew I. Banks, Zarmeen Zahid, Nathan T. Jones, Ziyad W. Sultan, and Cody J. Wenthur. Catalysts for change: the cellular neurobiology of psychedelics. Molecular Biology of the Cell 2021 32:12, 1135-1144.
  • L Richert, E Dyck. Psychedelic crossings: American mental health and LSD in the 1970s. Medical Humanities. 2020 Sep;46(3):184-191. doi: 10.1136/medhum-2018-011593. Epub 2019 Jun 23.
  • Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, Kalin NH, McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. PMID: 32098487.
  • Dahmane E, Hutson PR, Gobburu JVS. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. Clin Pharmacol Drug Dev. 2020 Apr 6. doi: 10.1002/cpdd.796. PMID: 32250059.
  • Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res. 2020 Feb;284:112749. doi: 10.1016/j.psychres.2020.112749. Epub 2020 Jan 2. PMID: 31931272.
  • Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL., Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020 Dec; 50(16):2655-2666. doi: 10.1017/S003329172000389X. Epub 2020 Nov 4.
  • N Schmitz, L Richert. Pharmacists and the future of cannabis medicine. Journal of the American Pharmacists Association  Jan-Feb 2020;60(1):207-211. doi: 10.1016/j.japh.2019.11.007. Epub 2019 Dec 20.
  • L Richert, M DeCloedt. Supple bodies, healthy minds: yoga, psychedelics and American mental health. Medical Humanities 2018; 44 (3), 193-200.
  • Nicholas CR, Henriquez KM, Gassman MC, Cooper KM, Muller D, Hetzel S, Brown RT, Cozzi NV, Thomas C, Hutson PR. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol. 2018 Jul;32(7):770-778. doi: 10.1177/0269881118780713. Epub 2018 Jun 27. PMID: 29945469.
  • Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017 Dec;56(12):1543-1554. doi: 10.1007/s40262-017-0540-6. PMID: 28353056.